Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes

Authors: Jose Luis Sánchez-Quesada, Irene Vinagre, Elena De Juan-Franco, Juan Sánchez-Hernández, Rosa Bonet-Marques, Francisco Blanco-Vaca, Jordi Ordóñez-Llanos, Antonio Pérez

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Qualitative alterations of lipoproteins underlie the high incidence of atherosclerosis in diabetes. The objective of this study was to assess the impact of low-density lipoprotein (LDL) subfraction phenotype on the qualitative characteristics of LDL and high-density lipoprotein (HDL) in patients with type 2 diabetes.

Methods

One hundred twenty two patients with type 2 diabetes in poor glycemic control and 54 healthy subjects were included in the study. Patients were classified according to their LDL subfraction phenotype. Seventy-seven patients presented phenotype A whereas 45 had phenotype B. All control subjects showed phenotype A. Several forms of modified LDL, HDL composition and the activity and distribution of lipoprotein-associated phospholipase A2 (Lp-PLA2) were analyzed.

Results

Oxidized LDL, glycated LDL and electronegative LDL were increased in both groups of patients compared with the control group. Patients with phenotype B had increased oxidized LDL and glycated LDL concentration than patients with phenotype A. HDL composition was abnormal in patients with diabetes, being these abnormalities more marked in patients with phenotype B. Total Lp-PLA2 activity was higher in phenotype B than in phenotype A or in control subjects. The distribution of Lp-PLA2 between HDL and apoB-containing lipoproteins differed in patients with phenotype A and phenotype B, with higher activity associated to apoB-containing lipoproteins in the latter.

Conclusions

The presence of LDL subfraction phenotype B is associated with increased oxidized LDL, glycated LDL and Lp-PLA2 activity associated to apoB-containing lipoproteins, as well as with abnormal HDL composition.
Appendix
Available only for authorised users
Literature
1.
go back to reference Witztum JL: Role of modified lipoproteins in diabetic macroangiopathy. Diabetes. 1997, 46 (Suppl 2): S112-S114.CrossRefPubMed Witztum JL: Role of modified lipoproteins in diabetic macroangiopathy. Diabetes. 1997, 46 (Suppl 2): S112-S114.CrossRefPubMed
2.
go back to reference Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ: The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 109-10.1186/1475-2840-11-109.PubMedCentralCrossRefPubMed Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ: The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 109-10.1186/1475-2840-11-109.PubMedCentralCrossRefPubMed
3.
go back to reference Pollin TI, Isakova T, Jablonski KA, De Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, et al: Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program. PLoS Genet. 2012, 8 (8): e1002895-10.1371/journal.pgen.1002895.PubMedCentralCrossRefPubMed Pollin TI, Isakova T, Jablonski KA, De Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, et al: Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program. PLoS Genet. 2012, 8 (8): e1002895-10.1371/journal.pgen.1002895.PubMedCentralCrossRefPubMed
4.
go back to reference Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004, 27 (6): 1496-1504. 10.2337/diacare.27.6.1496.CrossRefPubMed Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004, 27 (6): 1496-1504. 10.2337/diacare.27.6.1496.CrossRefPubMed
5.
go back to reference Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN: Glycation as an atherogenic modification of LDL. Curr Opin Lipidol. 2008, 19 (4): 378-384. 10.1097/MOL.0b013e328306a057.CrossRefPubMed Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN: Glycation as an atherogenic modification of LDL. Curr Opin Lipidol. 2008, 19 (4): 378-384. 10.1097/MOL.0b013e328306a057.CrossRefPubMed
6.
go back to reference Sanchez-Quesada JL, Benitez S, Ordonez-Llanos J: Electronegative low-density lipoprotein. Curr Opin Lipidol. 2004, 15 (3): 329-335. 10.1097/00041433-200406000-00014.CrossRefPubMed Sanchez-Quesada JL, Benitez S, Ordonez-Llanos J: Electronegative low-density lipoprotein. Curr Opin Lipidol. 2004, 15 (3): 329-335. 10.1097/00041433-200406000-00014.CrossRefPubMed
7.
go back to reference Sanchez-Quesada JL, Perez A, Caixas A, Rigla M, Payes A, Benitez S, Ordonez-Llanos J: Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab. 2001, 86 (7): 3243-3249. 10.1210/jc.86.7.3243.PubMed Sanchez-Quesada JL, Perez A, Caixas A, Rigla M, Payes A, Benitez S, Ordonez-Llanos J: Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab. 2001, 86 (7): 3243-3249. 10.1210/jc.86.7.3243.PubMed
8.
go back to reference Ha CY, Kim JY, Paik JK, Kim OY, Paik YH, Lee EJ, Lee JH: The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf). 2012, 76 (5): 674-682. 10.1111/j.1365-2265.2011.04244.x.CrossRef Ha CY, Kim JY, Paik JK, Kim OY, Paik YH, Lee EJ, Lee JH: The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf). 2012, 76 (5): 674-682. 10.1111/j.1365-2265.2011.04244.x.CrossRef
9.
go back to reference Kontush A, Chapman MJ: Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010, 21 (4): 312-318. 10.1097/MOL.0b013e32833bcdc1.CrossRefPubMed Kontush A, Chapman MJ: Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010, 21 (4): 312-318. 10.1097/MOL.0b013e32833bcdc1.CrossRefPubMed
10.
go back to reference Mackness MI, Durrington PN, Mackness B: The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs. 2004, 4 (4): 211-217. 10.2165/00129784-200404040-00002.CrossRefPubMed Mackness MI, Durrington PN, Mackness B: The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs. 2004, 4 (4): 211-217. 10.2165/00129784-200404040-00002.CrossRefPubMed
11.
go back to reference Rosenson RS, Stafforini DM: Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012, 53 (9): 1767-1782. 10.1194/jlr.R024190.PubMedCentralCrossRefPubMed Rosenson RS, Stafforini DM: Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012, 53 (9): 1767-1782. 10.1194/jlr.R024190.PubMedCentralCrossRefPubMed
12.
go back to reference Wagner AM, Perez A, Zapico E, Ordonez-Llanos J: Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care. 2003, 26 (7): 2048-2051. 10.2337/diacare.26.7.2048.CrossRefPubMed Wagner AM, Perez A, Zapico E, Ordonez-Llanos J: Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care. 2003, 26 (7): 2048-2051. 10.2337/diacare.26.7.2048.CrossRefPubMed
13.
go back to reference Sanchez-Quesada JL, Benitez S, Otal C, Franco M, Blanco-Vaca F, Ordonez-Llanos J: Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. J Lipid Res. 2002, 43 (5): 699-705.PubMed Sanchez-Quesada JL, Benitez S, Otal C, Franco M, Blanco-Vaca F, Ordonez-Llanos J: Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. J Lipid Res. 2002, 43 (5): 699-705.PubMed
14.
go back to reference Benitez S, Sanchez-Quesada JL, Lucero L, Arcelus R, Ribas V, Jorba O, Castellvi A, Alonso E, Blanco-Vaca F, Ordonez-Llanos J: Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids. Atherosclerosis. 2002, 160 (1): 223-232. 10.1016/S0021-9150(01)00565-2.CrossRefPubMed Benitez S, Sanchez-Quesada JL, Lucero L, Arcelus R, Ribas V, Jorba O, Castellvi A, Alonso E, Blanco-Vaca F, Ordonez-Llanos J: Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids. Atherosclerosis. 2002, 160 (1): 223-232. 10.1016/S0021-9150(01)00565-2.CrossRefPubMed
15.
go back to reference Ribas V, Sanchez-Quesada JL, Anton R, Camacho M, Julve J, Escola-Gil JC, Vila L, Ordonez-Llanos J, Blanco-Vaca F: Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res. 2004, 95 (8): 789-797. 10.1161/01.RES.0000146031.94850.5f.CrossRefPubMed Ribas V, Sanchez-Quesada JL, Anton R, Camacho M, Julve J, Escola-Gil JC, Vila L, Ordonez-Llanos J, Blanco-Vaca F: Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res. 2004, 95 (8): 789-797. 10.1161/01.RES.0000146031.94850.5f.CrossRefPubMed
16.
go back to reference Benitez S, Sanchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, Gonzalez-Sastre F, Ordonez-Llanos J: Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation. 2003, 108 (1): 92-96. 10.1161/01.CIR.0000072791.40232.8F.CrossRefPubMed Benitez S, Sanchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, Gonzalez-Sastre F, Ordonez-Llanos J: Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation. 2003, 108 (1): 92-96. 10.1161/01.CIR.0000072791.40232.8F.CrossRefPubMed
17.
go back to reference De Juan-Franco E, Pérez A, Ribas V, Sanchez- Hernandez JA, Blanco-Vaca F, Ordonez-Llanos J, Sanchez-Quesada JL: Standarization of a method to evaluate the antioxidant capacity of high-density lipoproteins. Int J Biomed Sci. 2009, 5 (4): 402-410.PubMedCentralPubMed De Juan-Franco E, Pérez A, Ribas V, Sanchez- Hernandez JA, Blanco-Vaca F, Ordonez-Llanos J, Sanchez-Quesada JL: Standarization of a method to evaluate the antioxidant capacity of high-density lipoproteins. Int J Biomed Sci. 2009, 5 (4): 402-410.PubMedCentralPubMed
18.
go back to reference Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005, 51 (12): 2264-2273. 10.1373/clinchem.2005.058404.CrossRefPubMed Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005, 51 (12): 2264-2273. 10.1373/clinchem.2005.058404.CrossRefPubMed
19.
go back to reference Hoogeveen RC, Ballantyne CM, Bang H, Heiss G, Duncan BB, Folsom AR, Pankow JS: Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia. 2007, 50 (1): 36-42.CrossRefPubMed Hoogeveen RC, Ballantyne CM, Bang H, Heiss G, Duncan BB, Folsom AR, Pankow JS: Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia. 2007, 50 (1): 36-42.CrossRefPubMed
20.
go back to reference Cohen MP, Lautenslager G, Shea E: Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem. 1993, 31 (11): 707-713.PubMed Cohen MP, Lautenslager G, Shea E: Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem. 1993, 31 (11): 707-713.PubMed
21.
go back to reference Younis NN, Soran H, Sharma R, Charlton-Menys V, Greenstein A, Elseweidy MM, Durrington PN: Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res. 2010, 7 (4): 289-295. 10.1177/1479164110383063.CrossRefPubMed Younis NN, Soran H, Sharma R, Charlton-Menys V, Greenstein A, Elseweidy MM, Durrington PN: Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res. 2010, 7 (4): 289-295. 10.1177/1479164110383063.CrossRefPubMed
22.
go back to reference Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003, 23 (10): 1881-1888. 10.1161/01.ATV.0000091338.93223.E8.CrossRefPubMed Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003, 23 (10): 1881-1888. 10.1161/01.ATV.0000091338.93223.E8.CrossRefPubMed
23.
go back to reference Camont L, Chapman MJ, Kontush A: Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011, 17 (10): 594-603. 10.1016/j.molmed.2011.05.013.CrossRefPubMed Camont L, Chapman MJ, Kontush A: Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011, 17 (10): 594-603. 10.1016/j.molmed.2011.05.013.CrossRefPubMed
24.
go back to reference Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005, 25 (5): 923-931. 10.1161/01.ATV.0000160551.21962.a7.CrossRefPubMed Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005, 25 (5): 923-931. 10.1161/01.ATV.0000160551.21962.a7.CrossRefPubMed
25.
go back to reference Koenig W, Khuseyinova N: Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009, 23 (1): 85-92. 10.1007/s10557-008-6135-6.CrossRefPubMed Koenig W, Khuseyinova N: Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009, 23 (1): 85-92. 10.1007/s10557-008-6135-6.CrossRefPubMed
26.
go back to reference Bhatti S, Hakeem A, Cilingiroglu M: Lp-PLA(2) as a marker of cardiovascular diseases. Curr Atheroscler Rep. 2010, 12 (2): 140-144. 10.1007/s11883-010-0095-6.CrossRefPubMed Bhatti S, Hakeem A, Cilingiroglu M: Lp-PLA(2) as a marker of cardiovascular diseases. Curr Atheroscler Rep. 2010, 12 (2): 140-144. 10.1007/s11883-010-0095-6.CrossRefPubMed
27.
go back to reference Nelson TL, Biggs ML, Kizer JR, Cushman M, Hokanson JE, Furberg CD, Mukamal KJ: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. J Clin Endocrinol Metab. 2012, 97 (5): 1695-1701. 10.1210/jc.2011-3026.PubMedCentralCrossRefPubMed Nelson TL, Biggs ML, Kizer JR, Cushman M, Hokanson JE, Furberg CD, Mukamal KJ: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. J Clin Endocrinol Metab. 2012, 97 (5): 1695-1701. 10.1210/jc.2011-3026.PubMedCentralCrossRefPubMed
28.
go back to reference Oei HH, Van Der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005, 111 (5): 570-575. 10.1161/01.CIR.0000154553.12214.CD.CrossRefPubMed Oei HH, Van Der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005, 111 (5): 570-575. 10.1161/01.CIR.0000154553.12214.CD.CrossRefPubMed
29.
go back to reference Hatoum IJ, Hu FB, Nelson JJ, Rimm EB: Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes. 2010, 59 (5): 1239-1243. 10.2337/db09-0730.PubMedCentralCrossRefPubMed Hatoum IJ, Hu FB, Nelson JJ, Rimm EB: Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes. 2010, 59 (5): 1239-1243. 10.2337/db09-0730.PubMedCentralCrossRefPubMed
30.
go back to reference Nelson TL, Kamineni A, Psaty B, Cushman M, Jenny NS, Hokanson J, Furberg C, Mukamal KJ: Lipoprotein-associated phospholipase A(2) and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study. Diabetologia. 2011, 54 (2): 329-333. 10.1007/s00125-010-1969-4.PubMedCentralCrossRefPubMed Nelson TL, Kamineni A, Psaty B, Cushman M, Jenny NS, Hokanson J, Furberg C, Mukamal KJ: Lipoprotein-associated phospholipase A(2) and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study. Diabetologia. 2011, 54 (2): 329-333. 10.1007/s00125-010-1969-4.PubMedCentralCrossRefPubMed
31.
go back to reference Kizer JR, Umans JG, Zhu J, Devereux RB, Wolfert RL, Lee ET, Howard BV: Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study. Diabetes Care. 2012, 35 (4): 840-847. 10.2337/dc11-1639.PubMedCentralCrossRefPubMed Kizer JR, Umans JG, Zhu J, Devereux RB, Wolfert RL, Lee ET, Howard BV: Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study. Diabetes Care. 2012, 35 (4): 840-847. 10.2337/dc11-1639.PubMedCentralCrossRefPubMed
32.
go back to reference Kujiraoka T, Iwasaki T, Ishihara M, Ito M, Nagano M, Kawaguchi A, Takahashi S, Ishi J, Tsuji M, Egashira T, et al: Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res. 2003, 44 (10): 2006-2014. 10.1194/jlr.D300021-JLR200.CrossRefPubMed Kujiraoka T, Iwasaki T, Ishihara M, Ito M, Nagano M, Kawaguchi A, Takahashi S, Ishi J, Tsuji M, Egashira T, et al: Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res. 2003, 44 (10): 2006-2014. 10.1194/jlr.D300021-JLR200.CrossRefPubMed
33.
go back to reference Mitsutake R, Miura S, Zhang B, Saku K: HDL-associated factors provide additional prognostic information for coronary artery disease as determined by multi-detector row computed tomography. Int J Cardiol. 2010, 143 (1): 72-78. 10.1016/j.ijcard.2009.01.058.CrossRefPubMed Mitsutake R, Miura S, Zhang B, Saku K: HDL-associated factors provide additional prognostic information for coronary artery disease as determined by multi-detector row computed tomography. Int J Cardiol. 2010, 143 (1): 72-78. 10.1016/j.ijcard.2009.01.058.CrossRefPubMed
34.
go back to reference Onat A, Hergenc G, Can G, Ugur M, Nartop F: Dual activity of serum lipoprotein-associated phospholipase A(2) yielding positive and inverse associations with cardiometabolic risk. Clin Chem Lab Med. 2011, 49 (8): 1349-1357.CrossRefPubMed Onat A, Hergenc G, Can G, Ugur M, Nartop F: Dual activity of serum lipoprotein-associated phospholipase A(2) yielding positive and inverse associations with cardiometabolic risk. Clin Chem Lab Med. 2011, 49 (8): 1349-1357.CrossRefPubMed
35.
go back to reference Rallidis LS, Tellis CC, Lekakis J, Rizos I, Varounis C, Charalampopoulos A, Zolindaki M, Dagres N, Anastasiou-Nana M, Tselepis AD: Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol. 2012, 60 (20): 2053-2060. 10.1016/j.jacc.2012.06.057.CrossRefPubMed Rallidis LS, Tellis CC, Lekakis J, Rizos I, Varounis C, Charalampopoulos A, Zolindaki M, Dagres N, Anastasiou-Nana M, Tselepis AD: Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol. 2012, 60 (20): 2053-2060. 10.1016/j.jacc.2012.06.057.CrossRefPubMed
36.
go back to reference Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A: Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2003, 88 (7): 3212-3217. 10.1210/jc.2003-030153.CrossRefPubMed Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A: Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2003, 88 (7): 3212-3217. 10.1210/jc.2003-030153.CrossRefPubMed
37.
go back to reference Sanchez-Quesada JL, Vinagre I, De Juan-Franco E, Sanchez-Hernandez J, Blanco-Vaca F, Ordonez-Llanos J, Perez A: Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. Am J Cardiol. 2012, 110 (1): 67-71. 10.1016/j.amjcard.2012.02.051.CrossRefPubMed Sanchez-Quesada JL, Vinagre I, De Juan-Franco E, Sanchez-Hernandez J, Blanco-Vaca F, Ordonez-Llanos J, Perez A: Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. Am J Cardiol. 2012, 110 (1): 67-71. 10.1016/j.amjcard.2012.02.051.CrossRefPubMed
Metadata
Title
Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes
Authors
Jose Luis Sánchez-Quesada
Irene Vinagre
Elena De Juan-Franco
Juan Sánchez-Hernández
Rosa Bonet-Marques
Francisco Blanco-Vaca
Jordi Ordóñez-Llanos
Antonio Pérez
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-112

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.